Search

Your search keyword '"Wacker HH"' showing total 3 results
Start Over Author "Wacker HH" Publication Year Range Last 10 years
3 results on '"Wacker HH"'

1. Mutations in the plasma cell clone identify mechanism of polyneuropathy in a case of POEMS syndrome associated with Castleman disease and multiple myeloma.

Author

Brioli A, Wyrwa A, Rüddel U, Yomade O, Lindig U, Franz W, Wacker HH, Gaßler N, Schweyer S, Chung HY, Axer H, Witte OW, Hochhaus A, and Schrenk KG

Subjects
Humans, Plasma Cells, Mutation, POEMS Syndrome complications, POEMS Syndrome diagnosis, POEMS Syndrome genetics, Multiple Myeloma complications, Multiple Myeloma genetics, Castleman Disease complications, Castleman Disease genetics
Published
2023
Full Text
View/download PDF

2. Molecular characteristics of diffuse large B-cell lymphoma in the Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin lymphomas (PETAL) trial: correlation with interim PET and outcome.

Author

Richter J, Hüttmann A, Rekowski J, Schmitz C, Gärtner S, Rosenwald A, Hansmann ML, Hartmann S, Möller P, Wacker HH, Feller A, Thorns C, Müller S, Dührsen U, and Klapper W

Subjects
Female, Humans, Lymphoma, Large B-Cell, Diffuse pathology, Lymphoma, Non-Hodgkin pathology, Male, Prognosis, Treatment Outcome, Lymphoma, Large B-Cell, Diffuse diagnostic imaging, Lymphoma, Non-Hodgkin complications, Lymphoma, Non-Hodgkin diagnostic imaging, Positron-Emission Tomography methods
Published
2019
Full Text
View/download PDF

3. Expression and pro-survival function of phospholipase Cγ2 in diffuse large B-cell lymphoma.

Author

Huynh MQ, Goßmann J, Gattenlöehner S, Klapper W, Wacker HH, Ramaswamy A, Bittner A, Kaiser U, and Neubauer A

Subjects
Apoptosis drug effects, Apoptosis genetics, Blotting, Western, Cell Line, Tumor, Cell Proliferation drug effects, Cell Proliferation genetics, Cell Survival drug effects, Cell Survival genetics, Estrenes pharmacology, Flow Cytometry, Humans, Immunohistochemistry, Lymphoma, Large B-Cell, Diffuse enzymology, Lymphoma, Large B-Cell, Diffuse pathology, Phosphodiesterase Inhibitors pharmacology, Phospholipase C gamma antagonists & inhibitors, Phospholipase C gamma metabolism, Pyrrolidinones pharmacology, RNA Interference, Reverse Transcriptase Polymerase Chain Reaction, Survival Analysis, Time Factors, Gene Expression Regulation, Enzymologic, Gene Expression Regulation, Neoplastic, Lymphoma, Large B-Cell, Diffuse genetics, Phospholipase C gamma genetics
Abstract

Diffuse large B-cell lymphoma (DLBCL) can be cured in about 60% of cases with immuno-chemotherapy. However, a large subset of patients with DLBCL do not go into remission, or relapse after first-line therapy. Further therapy options are therefore needed. Phospholipase Cγ2 (PLCγ2) is one of the key regulators of the B cell receptor signaling pathway, which targets several pro-proliferative factors, such as nuclear factor κB (NFκB), Ras and Akt. Using immunohistochemistry, we found that PLCγ2 was strongly expressed in 63% of cases of DLBCL. The PLC inhibitor U73122 had an inhibitory effect on cell proliferation and induced apoptosis and G0/G1 cell cycle arrest. Co-treatment with enzastaurin or the Src inhibitor pp2 together with U73122 had an additive effect on cell proliferation compared to U73122 alone. Unexpectedly, strong PLCγ2 expression was associated with better overall survival. In conclusion, PLCγ2 is strongly expressed in a significant number of DLBCLs and has prognostic implications. Inhibition of PLCγ2 could be a new target for lymphoma treatment.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results